Guo Cheng received his Ph.D. in bioinformatics from the University of Miami in 2011. After graduation, he worked as a bioinformatics analyst at the US Environmental Protection Agency and is currently a senior bioinformatics researcher at Columbia University School of Medicine.

He has been engaged in the analysis of the relationship between pathogenic microorganisms and diseases for many years. He has published more than ten SCI papers in the journals of mBio, Nature Communication and PNAS.

During his work at Columbia University, he led the invention of the BacCapSeq platform for effective diagnosis and monitoring of pathogenic bacteria, and systematically participated in multiple cohort studies of disease and microbiology. Among them, the second-generation sequencing-based gene detection platform BacCapSeq provides a full-spectrum and highly efficient infectious disease diagnosis platform, which improves the sequencing depth by 1000 times and the accuracy is greatly improved. There is no similar product on the market. , Has a strong clinical universality and applicability, the US patent is close to approval. After the publication of multiple scientific research results, it has also received extensive social response. The media covered by the report include Time Magazine, New York Daily and more than 100 media.